Tu canal independiente de oncología en español
Regístrate aquí para recibir más contenidos
Registrarse
OncoBites te trae los resúmenes y
presentaciones más relevantes del congreso
SABCS 2025
Top resúmenes y presentaciones
Central Nervous System Outcomes from the Phase III
PATINA Trial
RF4-01
DESTINY-Breast05 (interim analysis): T-DXd vs T-DM1 for
high-risk HER2+ BC with residual invasive disease after
neoadjuvant therapy; subgroups
RF6-01
Circulating tumor DNA (ctDNA) in human epidermal growth
factor receptor 2-positive (HER2[+]) Early Breast Cancer (EBC):
Translational analysis of PHERGain neoadjuvant tailored
treatment study
GS1-06
SABCS 2025
HER2+
SABCS 2025
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
Randomized phase II trial evaluating three anti-diarrheal
prophylaxis strategies in patients (pts) with HER2+/HR+ early
breast cancer (EBC) treated with extended adjuvant neratinib
(dianer geicam/2018-06).
PS3-10-28
Prospective Validation of HER2DX in Early HER2+ Breast Cancer:
Operational Feasibility of Centralized Genomic Screening in the
DEFINITIVE Trial. Real-Time Insights from the First 80 Screened
Patients
PS4-01-07
HER2CLIMB-05: A randomized, double-blind, phase 3 study of
tucatinib versus placebo in combination with trastuzumab and
pertuzumab as maintenance therapy for HER2+ metastatic
breast cancer.
GS1-01
Sacituzumab govitecan vs chemotherapy as first therapy
after endocrine therapy in HR+/HER2− (IHC 0, 1+, 2+/ISH−)
metastatic breast cancer: Primary results from ASCENT-07
GS1-09
Giredestrant vs standard-of-care endocrine therapy as
adjuvant treatment for patients with estrogen
receptor-positive, HER2-negative early breast cancer:
Results from the global Phase III lidERA Breast Cancer trial
GS1-10
Multimodal artificial intelligence (AI) models integrating image,
clinical, and molecular data for predicting early and late breast
cancer recurrence in TAILORx
GS1-08
SABCS 2025
LUMINAL
SABCS 2025
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
Heating up cold tumors: single-cell mapping of immune and
adenosine pathway reprogramming in luminal B breast cancer
(Neo-CheckRay trial)
GS2-04
Primary Results from the HR+/HER2- Cohort of TBCRC-053
(P-RAD): A Randomized Trial of No, Low, or High Dose
Preoperative RADiation with Pembrolizumab and
Chemotherapy in Node-Positive, HER2-Negative Breast Cancer
GS2-05
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR )
assay to predict benefit from extended endocrine therapy in the
NRG/NSABP B-42 trial
GS3-05
Prognostic Markers in Residual Tumors after neoadjuvant
chemotherapy (NACT) for Early Triple-negative Breast
Cancer (TNBC) – a Pooled Analysis from nine Neoadjuvant
GBG/AGO-B Trials
RF2-01
Neo-n (neon): three-year event-free survival and
ultrasensitive ctdna dynamics in early triple-negative breast
cancer (tnbc) treated with neoadjuvant
carboplatin/paclitaxel and nivolumab
PD7-10
Tbcrc 056: A phase 2 study of neoadjuvant niraparib with
dostarlimab for patients with BRCA- or PALB2-mutated breast
cancer: results from the TNBC cohorts
RF5-02
SABCS 2025
TRIPLE NEGATIVO
SABCS 2025
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
Impact of Immune Checkpoint Inhibition (CPI) on Fertility in
Young Women with Early Triple-Negative Breast Cancer (TNBC)
receiving neoadjuvant Chemotherapy (NACT): A Prospective
Substudy of the NSABP B-59/GBG-96-GeparDouze Trial
RF2-05
Impact of neoadjuvant pembrolizumab on ovarian function in
young patients with triple-negative breast cancer (TNBC):
Longitudinal analysis from NeoSTOP and NeoPACT trials
PD7-11
Olympian: a phase 2, multicenter, open-label study to assess the
efficacy and safety of neoadjuvant olaparib monotherapy and
olaparib plus durvalumab in patients with brca mutations and
early-stage her2-negative breast cancer
RF5-03